Global Oncology Drugs Market Synopsis

Global Oncology Drugs Market Size Was Valued at USD 221.36 Billion in 2023 and is Projected to Reach USD 474.06 Billion by 2032, Growing at a CAGR of 8.83% From 2024-2032.

Oncology is the branch of medicine that includes cancer prevention, diagnosis, treatment, and study. Cancer describes the irregular growth of cells that results in a huge mass known as a tumour.

• Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Oncology drugs contain a range of different types of medicines, for instance, chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies. Different types of drugs are also existing to support treat the side effects of oncology drugs.  
• An oncologist is a healthcare provider who specializes in diagnosing and treating cancer. Oncologists manage cancer treatment throughout the illness. Healthcare workers treat cancer using chemotherapy, hormonal therapies, immunotherapy, and other targeted treatments. People often think of the medical oncologist as their primary cancer specialist. Most medical oncologists also specify hematology.
• Paediatric oncology is a vital medical field that treats pediatric cancer types, including serious lymphocytic leukemia, neuroblastoma, and brain and other central nervous system tumors. Treatment often changes from adult oncology. Pediatric oncology treatment may contain surgery, chemotherapy, radiation therapy, immunotherapy, and stem cell transplant.
• Oncologists specialize in managing drug treatments for people with primary and advanced cancers that affect the tissues, muscles, bones, and connective tissue. Early-stage cancers may be treated with surgery or radiation therapy alone and may not essential the care of an oncologist.

Global Oncology Drugs Market Trend Analysis

Increased Alcohol and Tobacco Consumption on Health and Society

• Alcohol and tobacco use are related to several adverse health significances, including an increased risk of certain types of cancer. For instance, epidemiological studies initiate that alcohol drinking can increase the risk for cancers of the higher aerodigestive tract, stomach, large bowel, liver, and breast, with advanced levels of consumption leading to greater growth in risk.
• Cigarettes contain amounts of chemicals, with many known carcinogens. The carcinogenic role of cigarettes contrasts depending on the cigarette product. The chemical products of alcohol absorption are also explored to be toxic and assumed to cause DNA modifications that main to cancers.
• Alcohol increases the carcinogenic significance of tobacco. For example, it might increase the synthesis of specific enzymes that chance the chemical tobacco tar is created by burning tobacco into carcinogens.
• Every alcoholic drink covers ethanol. When consuming alcohol, the body breaks down the ethanol into acetaldehyde and other chemicals. Acetaldehyde damages DNA and stops bodies from restoring the damage. That damage over time may be responsible for cancer.
• Smoking causes cancer by damaging the DNA of private cells. When individuals inhale tobacco smoke into their lungs the smoke also touches the nose, mouth, voice box, throat, and gullet. The hazardous chemicals in tobacco smoke can also injury organs that are not in the route because they are absorbed into the circulation in the lungs.

Increasing Technological Advancements

• An increase in the rate of cancer rate worldwide combined with improved mortality in some of the malignancies endures poses a challenge to the biomedical scientific community for the actual administration of cancer. Prevention being a realistic prospect only in a few types of cancers, technological advancements in cancer diagnostics with accurate determination of location, size, stage, and molecular features, are immediately needed for cancer treatment, due to a worldwide increase in cancer-related mortality.
• The method for diagnosis as a part of the clinical management of cancer contains a physical inspection for irregularities in various anatomical locations and a battery of laboratory inquiries using blood and urine combined with a combination of radiologic and nuclear medicine-based non-invasive imaging modalities like electronic X-ray scan ultrasonography, magnetic resonance imaging (MRI), bone scan, positron emission tomography followed by minimally invasive biopsy or invasive (surgical) biopsy joined with histo-pathological inspection to found the identity and stage of the cancer.
• Cancer diagnosis is quickly evolving due to constant developments in knowledge of the disease and enhancements in technology that growth the feasibility of consistent diagnostic approaches. There are numerous cancer diagnostic modalities such as 2D and 3D imaging of tumors using positron emission tomography (PET), MRI, single photon emission computed tomography (SPECT), computed tomography (CT), X-ray imaging, and analysis of molecular (metabolic, proteomic, genomic, and transcriptomic) signatures of cancer cells, thus leveraging the cancer diagnosis and management.

Global Oncology Drugs Market Segment Analysis:

Global Oncology Drugs Market is Segmented on the basis of Diagnostics & Treatment, Treatment, Drugs Class, Dosage Form, Indication, Distribution Channel, And End-user.

By Diagnostics & Treatment, the Treatment segment is expected to dominate the market during the forecast period

• Cancer treatment for patients for many years which includes surgery, radiation therapy, and chemotherapy as only treatments in combination. But newly, many ways involved in cancer therapy progression and targeted enhanced intensely, with combinatorial strategies, connecting multiple targeted therapies or “traditional” chemotherapeutics, such as the taxanes and platinum compounds, originating to have a synergistic effect. such as drugs, biological molecules, and immune-mediated therapies, are being used for treatment even if the included therapy level has not stretched struggles the humanity rate and declines the prolonged survival time for metastatic cancer.
• The creation of a new uprising in neoplastic cancer or targeting drugs depends on the pathways and characteristics of diverse tumor objects. Chemotherapy is measured as the most effective and broadly used modality in treating cancers as used without help and in combination with radiotherapy. Genotoxicity is chemotherapy drugs target the tumor cells mostly making reactive oxygen species that largely abolish tumor cells.
• Chemotherapy drugs to destroy cancer cells. This specific cancer therapy, cancer cells are prohibited from increasing, dividing, and generating new cells. Numerous cancers can be treated by chemotherapy. Doctors may state chemotherapy as normal chemotherapy, conventional chemotherapy, or cytotoxic chemotherapy. The medication chemotherapy has an overall body-wide impact. This indicates that it circulates through the body via the circulation. Chemotherapy comes in a variety of forms.

By Application, the Lung Cancer segment held the largest share in 2023

• Lung cancer is one of the most common cancers and a huge number of people die of this disease each year. The disease is often exposed in a late stage, but also in previous stages lung cancer patients have inferior outcomes than patients with other cancers. Even without dispersion to other tissues, during stage I, the existence rate of lung cancer is under 70%. For instance, in breast cancer, there is 95% existence in the stage.
• Lung cancer is the unrestrained growing of irregular cells that starts in one or both lungs. These irregular cells do not transmit out the roles of normal lung cells and do not change into healthy lung tissue. The abnormal cells start to form tumors that inhibit the working of the lung.
• A diagnosis of lung cancer is serious, but treatments have enhanced extremely in recent years. People with lung cancer do improve if diagnosed with early-stage disease, so identifying lung cancer symptoms is significant. Lung cancer can frequently be present without indications, lung cancer screening is also an important tool to detect lung cancer initially in people who are at high risk.

Global Oncology Drugs Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America has a developed healthcare system, which includes hospitals, specialized cancer centers, research institutions, and medical universities. The strong healthcare system in the area allows for effective identification, care, and control of a range of illnesses, such as cancer.
• North America spends a significant amount on healthcare, showing a strong focus on healthcare services and advancements. This investment in finances supports the growth and acceptance of new technologies, state-of-the-art therapies, and advanced treatment choices.
• The region is recognized for its significant contributions in oncology research, clinical trials, and drug development which give North America an upper hand in the market.
• The region has been an early adopter of technological advancements in the healthcare sector due to this North America has witnessed remarkable progress in precision medicine, genomic profiling, molecular diagnostics, imaging technologies, and targeted therapies.

Active Key Players in the Global Oncology Drugs Market

• Roche Holding AG (Switzerland)
• Bristol Myers Squibb (U.S.)
• Kura Oncology, Inc.  (U.S.)
• Johnson & Johnson (U.S.)
• Pfizer Inc.  (U.S.)
• AstraZeneca (U.K.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Abbott Laboratorie (U.S.)
• Amgen Inc.  (U.S.)
• Sanofi SA - France
• Bristol-Myers Squibb Company (U.S.)
• Gilead Sciences Inc (U.S.)
• Vertex Pharmaceuticals Inc.  (U.S.)
• Regeneron Pharmaceuticals Inc.  (U.S.)
• GSK plc.  (U.K.)
• Daiichi Sankyo Company Ltd.  Japan
• Takeda Pharmaceutical Company Ltd.  (Japan)
• Moderna Inc (U.S.)
• Biogen Inc. (U.S.)
• BioNTech SE (Germany)
• Astellas Pharma Inc. (Japan)
• Illumina Inc. ((U.S.))
• Beigene Ltd. (China)
• Otsuka Pharmaceutical Ltd. (Japan)
• Incyte Corporation ((U.S.))
• Teva Pharmaceutical Industries Ltd. (Israel)
• Dr. Reddy’s Laboratories Limited (India)
• Jazz Pharmaceuticals plc (Ireland)
• Oncology Convergence, Inc ((U.S.))
• Oncology Systems Limited (U.K.)
• GenesisCare USA, Inc. ((U.S.))
• Integrated Oncology Centres (Hong Kong)
• Tennessee Oncology ((U.S.))
• Maryland Oncology Hematology ((U.S.))
• Minnesota Oncology ((U.S.))
• Arizona Oncology ((U.S.))
• Highlands Oncology ((U.S.))
• GenPath Oncology ((U.S.))
• HCG Manavata Oncology LLP (India)
• New York Oncology Hematology ((U.S.))
• McGill Oncology (Canada)
• NeoGenomics Laboratories, Inc. ((U.S.))
• Valley Health System ((U.S.))
• Jupiter Medical Center ((U.S.))
• GBMC HealthCare ((U.S.))
• Duly Health and Care ((U.S.))
• Alliance Healthcare Services, Inc. ((U.S.)) and other Active Players.

Key Industry Developments in the Global Oncology Drugs Market:

• In March 2024, Roche Pharma India launched Vabysmo, a medication for neovascular age-related macular degeneration and diabetic macular edema in India. The drug is cost-effective and collaborates with government and insurance companies for patient access. Vabysmo achieves global sales and offers durable treatment for retinal vision loss.
• In January 2024, BDR Pharmaceuticals has, in a global first, introduced the prostate cancer drug enzalutamide in oral solution form. The formulation provides an effective dosage form, with fewer side effects than existing oral dosage forms of enzalutamide.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Drug Class
 3.2 By Therapy
 3.3 By Cancer Type
 3.4 By Dosage Form

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  3.5.1 Drivers
  3.5.2 Restraints
  3.5.3 Opportunities
  3.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 4: Oncology Drugs Market by Drug Class
 4.1 Oncology Drugs Market Overview Snapshot and Growth Engine
 4.2 Oncology Drugs Market Overview
 4.3 Targeted Drugs
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size (2016-2028F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Targeted Drugs: Grographic Segmentation
 4.4 Hormonal Drugs
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size (2016-2028F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Hormonal Drugs: Grographic Segmentation
 4.5 Cytotoxic Drugs
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size (2016-2028F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Cytotoxic Drugs: Grographic Segmentation
 4.6 Others
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size (2016-2028F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Others: Grographic Segmentation

Chapter 5: Oncology Drugs Market by Therapy
 5.1 Oncology Drugs Market Overview Snapshot and Growth Engine
 5.2 Oncology Drugs Market Overview
 5.3 Targeted Therapy
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Targeted Therapy: Grographic Segmentation
 5.4 Chemotherapy
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Chemotherapy: Grographic Segmentation
 5.5 Immunotherapy
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Immunotherapy: Grographic Segmentation

Chapter 6: Oncology Drugs Market by Cancer Type
 6.1 Oncology Drugs Market Overview Snapshot and Growth Engine
 6.2 Oncology Drugs Market Overview
 6.3 Colorectal Cancer
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Colorectal Cancer: Grographic Segmentation
 6.4 Lung Cancer
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Lung Cancer: Grographic Segmentation
 6.5 Stomach Cancer
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Stomach Cancer: Grographic Segmentation
 6.6 Prostate Cancer
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Prostate Cancer: Grographic Segmentation
 6.7 Breast Cancer
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Breast Cancer: Grographic Segmentation

Chapter 7: Oncology Drugs Market by Dosage Form
 7.1 Oncology Drugs Market Overview Snapshot and Growth Engine
 7.2 Oncology Drugs Market Overview
 7.3 Solid
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Solid: Grographic Segmentation
 7.4 Liquid
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Liquid: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Oncology Drugs Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Oncology Drugs Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Oncology Drugs Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 GENENTECH
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 INC. (US)
 8.4 ELI LILLY AND COMPANY (UNITED STATES)
 8.5 PFIZER INC. (US)
 8.6 BRISTOL-MYERS SQUIBB COMPANY (US)
 8.7 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
 8.8 NOVARTIS AG (SWITZERLAND)
 8.9 ASTRAZENECA (UK)
 8.10 GLAXOSMITHKLINE PLC. (UK)
 8.11 SANOFI (FRANCE)
 8.12 BAYER AG (GERMANY)

Chapter 9: Global Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Drug Class
  9.2.1 Targeted Drugs
  9.2.2 Hormonal Drugs
  9.2.3 Cytotoxic Drugs
  9.2.4 Others
 9.3 Historic and Forecasted Market Size By Therapy
  9.3.1 Targeted Therapy
  9.3.2 Chemotherapy
  9.3.3 Immunotherapy
 9.4 Historic and Forecasted Market Size By Cancer Type
  9.4.1 Colorectal Cancer
  9.4.2 Lung Cancer
  9.4.3 Stomach Cancer
  9.4.4 Prostate Cancer
  9.4.5 Breast Cancer
 9.5 Historic and Forecasted Market Size By Dosage Form
  9.5.1 Solid
  9.5.2 Liquid

Chapter 10: North America Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Drug Class
  10.4.1 Targeted Drugs
  10.4.2 Hormonal Drugs
  10.4.3 Cytotoxic Drugs
  10.4.4 Others
 10.5 Historic and Forecasted Market Size By Therapy
  10.5.1 Targeted Therapy
  10.5.2 Chemotherapy
  10.5.3 Immunotherapy
 10.6 Historic and Forecasted Market Size By Cancer Type
  10.6.1 Colorectal Cancer
  10.6.2 Lung Cancer
  10.6.3 Stomach Cancer
  10.6.4 Prostate Cancer
  10.6.5 Breast Cancer
 10.7 Historic and Forecasted Market Size By Dosage Form
  10.7.1 Solid
  10.7.2 Liquid
 10.8 Historic and Forecast Market Size by Country
  10.8.1 U.S.
  10.8.2 Canada
  10.8.3 Mexico

Chapter 11: Europe Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Drug Class
  11.4.1 Targeted Drugs
  11.4.2 Hormonal Drugs
  11.4.3 Cytotoxic Drugs
  11.4.4 Others
 11.5 Historic and Forecasted Market Size By Therapy
  11.5.1 Targeted Therapy
  11.5.2 Chemotherapy
  11.5.3 Immunotherapy
 11.6 Historic and Forecasted Market Size By Cancer Type
  11.6.1 Colorectal Cancer
  11.6.2 Lung Cancer
  11.6.3 Stomach Cancer
  11.6.4 Prostate Cancer
  11.6.5 Breast Cancer
 11.7 Historic and Forecasted Market Size By Dosage Form
  11.7.1 Solid
  11.7.2 Liquid
 11.8 Historic and Forecast Market Size by Country
  11.8.1 Germany
  11.8.2 U.K.
  11.8.3 France
  11.8.4 Italy
  11.8.5 Russia
  11.8.6 Spain

Chapter 12: Asia-Pacific Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Drug Class
  12.4.1 Targeted Drugs
  12.4.2 Hormonal Drugs
  12.4.3 Cytotoxic Drugs
  12.4.4 Others
 12.5 Historic and Forecasted Market Size By Therapy
  12.5.1 Targeted Therapy
  12.5.2 Chemotherapy
  12.5.3 Immunotherapy
 12.6 Historic and Forecasted Market Size By Cancer Type
  12.6.1 Colorectal Cancer
  12.6.2 Lung Cancer
  12.6.3 Stomach Cancer
  12.6.4 Prostate Cancer
  12.6.5 Breast Cancer
 12.7 Historic and Forecasted Market Size By Dosage Form
  12.7.1 Solid
  12.7.2 Liquid
 12.8 Historic and Forecast Market Size by Country
  12.8.1 China
  12.8.2 India
  12.8.3 Japan
  12.8.4 Southeast Asia

Chapter 13: South America Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Drug Class
  13.4.1 Targeted Drugs
  13.4.2 Hormonal Drugs
  13.4.3 Cytotoxic Drugs
  13.4.4 Others
 13.5 Historic and Forecasted Market Size By Therapy
  13.5.1 Targeted Therapy
  13.5.2 Chemotherapy
  13.5.3 Immunotherapy
 13.6 Historic and Forecasted Market Size By Cancer Type
  13.6.1 Colorectal Cancer
  13.6.2 Lung Cancer
  13.6.3 Stomach Cancer
  13.6.4 Prostate Cancer
  13.6.5 Breast Cancer
 13.7 Historic and Forecasted Market Size By Dosage Form
  13.7.1 Solid
  13.7.2 Liquid
 13.8 Historic and Forecast Market Size by Country
  13.8.1 Brazil
  13.8.2 Argentina

Chapter 14: Middle East & Africa Oncology Drugs Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Drug Class
  14.4.1 Targeted Drugs
  14.4.2 Hormonal Drugs
  14.4.3 Cytotoxic Drugs
  14.4.4 Others
 14.5 Historic and Forecasted Market Size By Therapy
  14.5.1 Targeted Therapy
  14.5.2 Chemotherapy
  14.5.3 Immunotherapy
 14.6 Historic and Forecasted Market Size By Cancer Type
  14.6.1 Colorectal Cancer
  14.6.2 Lung Cancer
  14.6.3 Stomach Cancer
  14.6.4 Prostate Cancer
  14.6.5 Breast Cancer
 14.7 Historic and Forecasted Market Size By Dosage Form
  14.7.1 Solid
  14.7.2 Liquid
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Saudi Arabia
  14.8.2 South Africa

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ONCOLOGY DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ONCOLOGY DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ONCOLOGY DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. ONCOLOGY DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. ONCOLOGY DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. ONCOLOGY DRUGS MARKET BY DRUG CLASS
TABLE 008. TARGETED DRUGS MARKET OVERVIEW (2016-2028)
TABLE 009. HORMONAL DRUGS MARKET OVERVIEW (2016-2028)
TABLE 010. CYTOTOXIC DRUGS MARKET OVERVIEW (2016-2028)
TABLE 011. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 012. ONCOLOGY DRUGS MARKET BY THERAPY
TABLE 013. TARGETED THERAPY MARKET OVERVIEW (2016-2028)
TABLE 014. CHEMOTHERAPY MARKET OVERVIEW (2016-2028)
TABLE 015. IMMUNOTHERAPY MARKET OVERVIEW (2016-2028)
TABLE 016. ONCOLOGY DRUGS MARKET BY CANCER TYPE
TABLE 017. COLORECTAL CANCER MARKET OVERVIEW (2016-2028)
TABLE 018. LUNG CANCER MARKET OVERVIEW (2016-2028)
TABLE 019. STOMACH CANCER MARKET OVERVIEW (2016-2028)
TABLE 020. PROSTATE CANCER MARKET OVERVIEW (2016-2028)
TABLE 021. BREAST CANCER MARKET OVERVIEW (2016-2028)
TABLE 022. ONCOLOGY DRUGS MARKET BY DOSAGE FORM
TABLE 023. SOLID MARKET OVERVIEW (2016-2028)
TABLE 024. LIQUID MARKET OVERVIEW (2016-2028)
TABLE 025. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 026. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 027. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 028. NORTH AMERICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 029. N ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 030. EUROPE ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 031. EUROPE ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 032. EUROPE ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 033. EUROPE ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 034. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 035. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 036. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 037. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 038. ASIA PACIFIC ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 039. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 043. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 044. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 045. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 046. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY THERAPY (2016-2028)
TABLE 047. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY CANCER TYPE (2016-2028)
TABLE 048. SOUTH AMERICA ONCOLOGY DRUGS MARKET, BY DOSAGE FORM (2016-2028)
TABLE 049. ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 050. GENENTECH: SNAPSHOT
TABLE 051. GENENTECH: BUSINESS PERFORMANCE
TABLE 052. GENENTECH: PRODUCT PORTFOLIO
TABLE 053. GENENTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. INC. (US): SNAPSHOT
TABLE 054. INC. (US): BUSINESS PERFORMANCE
TABLE 055. INC. (US): PRODUCT PORTFOLIO
TABLE 056. INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. ELI LILLY AND COMPANY (UNITED STATES): SNAPSHOT
TABLE 057. ELI LILLY AND COMPANY (UNITED STATES): BUSINESS PERFORMANCE
TABLE 058. ELI LILLY AND COMPANY (UNITED STATES): PRODUCT PORTFOLIO
TABLE 059. ELI LILLY AND COMPANY (UNITED STATES): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. PFIZER INC. (US): SNAPSHOT
TABLE 060. PFIZER INC. (US): BUSINESS PERFORMANCE
TABLE 061. PFIZER INC. (US): PRODUCT PORTFOLIO
TABLE 062. PFIZER INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. BRISTOL-MYERS SQUIBB COMPANY (US): SNAPSHOT
TABLE 063. BRISTOL-MYERS SQUIBB COMPANY (US): BUSINESS PERFORMANCE
TABLE 064. BRISTOL-MYERS SQUIBB COMPANY (US): PRODUCT PORTFOLIO
TABLE 065. BRISTOL-MYERS SQUIBB COMPANY (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): SNAPSHOT
TABLE 066. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 067. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 068. F. HOFFMANN-LA ROCHE LTD (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. NOVARTIS AG (SWITZERLAND): SNAPSHOT
TABLE 069. NOVARTIS AG (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 070. NOVARTIS AG (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 071. NOVARTIS AG (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. ASTRAZENECA (UK): SNAPSHOT
TABLE 072. ASTRAZENECA (UK): BUSINESS PERFORMANCE
TABLE 073. ASTRAZENECA (UK): PRODUCT PORTFOLIO
TABLE 074. ASTRAZENECA (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. GLAXOSMITHKLINE PLC. (UK): SNAPSHOT
TABLE 075. GLAXOSMITHKLINE PLC. (UK): BUSINESS PERFORMANCE
TABLE 076. GLAXOSMITHKLINE PLC. (UK): PRODUCT PORTFOLIO
TABLE 077. GLAXOSMITHKLINE PLC. (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. SANOFI (FRANCE): SNAPSHOT
TABLE 078. SANOFI (FRANCE): BUSINESS PERFORMANCE
TABLE 079. SANOFI (FRANCE): PRODUCT PORTFOLIO
TABLE 080. SANOFI (FRANCE): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. BAYER AG (GERMANY): SNAPSHOT
TABLE 081. BAYER AG (GERMANY): BUSINESS PERFORMANCE
TABLE 082. BAYER AG (GERMANY): PRODUCT PORTFOLIO
TABLE 083. BAYER AG (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ONCOLOGY DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ONCOLOGY DRUGS MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. TARGETED DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 013. HORMONAL DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 014. CYTOTOXIC DRUGS MARKET OVERVIEW (2016-2028)
FIGURE 015. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 016. ONCOLOGY DRUGS MARKET OVERVIEW BY THERAPY
FIGURE 017. TARGETED THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 018. CHEMOTHERAPY MARKET OVERVIEW (2016-2028)
FIGURE 019. IMMUNOTHERAPY MARKET OVERVIEW (2016-2028)
FIGURE 020. ONCOLOGY DRUGS MARKET OVERVIEW BY CANCER TYPE
FIGURE 021. COLORECTAL CANCER MARKET OVERVIEW (2016-2028)
FIGURE 022. LUNG CANCER MARKET OVERVIEW (2016-2028)
FIGURE 023. STOMACH CANCER MARKET OVERVIEW (2016-2028)
FIGURE 024. PROSTATE CANCER MARKET OVERVIEW (2016-2028)
FIGURE 025. BREAST CANCER MARKET OVERVIEW (2016-2028)
FIGURE 026. ONCOLOGY DRUGS MARKET OVERVIEW BY DOSAGE FORM
FIGURE 027. SOLID MARKET OVERVIEW (2016-2028)
FIGURE 028. LIQUID MARKET OVERVIEW (2016-2028)
FIGURE 029. NORTH AMERICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. EUROPE ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. ASIA PACIFIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. SOUTH AMERICA ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)